Listen
Reason for request
Amendment to the inclusion conditions in the indication for juvenile idiopathic arthritis (JIA). The indication is no longer restricted to adolescents from 13 to 17 years but has been expanded to include paediatric patients and adolescents aged from 4 to 12 years. Inclusion on the list of medicines refundable by National Insurance and approved for use by hospitals of a new form for paediatric use only (separate opinion). Amendment to the conditions of inclusion in the indication for Crohn's Disease (removal of the need to combine with corticosteroids when starting treatment with HUMIRA). Update of Therapeutic Information Sheet.
Clinical Benefit
| Substantial |
Le service médical rendu par ces spécialités est important dans l'arthrite juvénile idiopathique chez les patients âgés de 4 à 12 ans. |
Clinical Added Value
| no clinical added value |
HUMIRA n'apporte pas d'amélioration du service médical rendu (niveau V) dans la prise en charge de l'arthrite juvénile idiopathique polyarticulaire évolutive, chez l'adolescent âgé de 4 à 12 ans, en cas de réponse insuffisante à un ou plusieurs traitements de fond. |
Documents
Contact Us
Évaluation des médicaments
